Clin Lab. 2022 Nov 1;68(11). doi: 10.7754/Clin.Lab.2022.220229.
Hepatitis B virus-associated decompensated cirrhosis (HBV-DeCi) has a high risk of short-term mortality. However, it is difficult to predict the prognosis of these patients in clinical practice. The present study sought to determine whether red cell distribution width-to-lymphocyte ratio (RLR) is related to adverse outcomes in HBV-DeCi patients.
One hundred and seventy HBV-DeCi patients were recruited for the study. The patients were divided into survivor and non-survivor groups according to the 30-day mortality. Multivariate logistic analyses and area under the receiver operating characteristic curve (AUROC) values were used to determine the performance of RLR as a prognostic predictor in HBV-DeCi.
The 30-day mortality of the HBV-DeCi patients was 13.5% (23/170). RLR was higher in the non-survivor group compared with the survivor group. Multivariate analysis identified RLR as an independent factor for mortality in HBV-DeCi patients. The AUROC analysis demonstrated that RLR can be a reliable prognostic biomarker for HBV-DeCi patients.
RLR could be utilized as a short-term prognostic indicator for HBV-DeCi patients.
乙型肝炎病毒相关失代偿性肝硬化（HBV-DeCi）具有较高的短期死亡率。然而，在临床实践中很难预测这些患者的预后。本研究旨在确定红细胞分布宽度与淋巴细胞比值（RLR）是否与 HBV-DeCi 患者的不良结局相关。
本研究纳入了 170 例 HBV-DeCi 患者。根据 30 天死亡率将患者分为存活组和死亡组。采用多变量逻辑分析和受试者工作特征曲线（AUROC）下面积值来确定 RLR 在 HBV-DeCi 患者预后预测中的性能。
HBV-DeCi 患者的 30 天死亡率为 13.5%（23/170）。死亡组的 RLR 高于存活组。多变量分析确定 RLR 是 HBV-DeCi 患者死亡的独立因素。AUROC 分析表明，RLR 可作为 HBV-DeCi 患者可靠的预后生物标志物。
RLR 可作为 HBV-DeCi 患者短期预后指标。
